Ad
related to: meds that cause hyperphosphatemia- How It Works
See How This Treatment Could
Help Your Patients
- Dosing Information
View Dosing & Prescribing
Information For This Treatment
- See Expert Videos
Hear From Experts On
Hyperphosphatemia Management
- Mechanism Of Action
Learn About MOA For
This Treatment Option
- Safety Information
Important Safety Information
And Possible Side Effects
- Why This Treatment?
Learn How This Treatment Could
Help Your Patients
- How It Works
Search results
Results From The WOW.Com Content Network
Hyperphosphatemia. Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. [1] Most people have no symptoms while others develop calcium deposits in the soft tissue. [1] The disorder is often accompanied by low calcium blood levels, which can result in muscle spasms.
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer ...
Phosphate binder. Phosphate binders are medications used to reduce the absorption of dietary phosphate; they are taken along with meals and snacks. They are frequently used in people with chronic kidney failure (CKF), who are less able to excrete phosphate, resulting in an elevated serum phosphate.
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1][2] In these situations they decrease the need for blood transfusions. [2]
Sucroferric oxyhydroxide. Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). [6] It is used in form of chewable tablets.
Tumor lysis syndrome. Tumor lysis syndrome (TLS) is a group of metabolic abnormalities that can occur as a complication from the treatment of cancer, [ 1 ] where large amounts of tumor cells are killed off (lysed) from the treatment, releasing their contents into the bloodstream. This occurs most commonly after the treatment of lymphomas and ...
Renal osteodystrophy is currently defined as an alteration of bone morphology in patients with chronic kidney disease (CKD). [1] It is one measure of the skeletal component of the systemic disorder of chronic kidney disease-mineral and bone disorder (CKD-MBD). [1][2][3] The term "renal osteodystrophy" was coined in 1943, [4] 60 years after an ...
If the underlying cause of the hypocalcemia can be addressed, the hyperparathyroidism will resolve. In people with chronic kidney failure, treatment consists of dietary restriction of phosphorus; supplements containing an active form of vitamin D, such as calcitriol, doxercalciferol, paricalcitol; and phosphate binders, which are either calcium-based and non-calcium based.